Navigation Links
Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinson's Disease
Date:10/25/2012

ly improved delivery technologies capable of getting MANF to the substantia nigra, could complement or replace drugs in development that may get to market ahead of MANF, especially in later-stage patients.

"Today's announcement is transformational for Amarantus from a scientific data standpoint," said Gerald E. Commissiong, President & CEO of Amarantus. "Despite the many clear scientific advantages we believe MANF possesses over GDNF, most notably impacting protein folding and modulating toxic calcium levels, the Company had previously been unable to point to a definitive behavioural animal model data to show improved benefit of MANF over GDNF in the Parkinson's disease indication. The data we now have validates the approach we have been taking over the last several years, and we believe that it will allow us to attract the interest of investment firms and potential partners who will be able to now characterize the substantial opportunity our technology represents. We believe that we are well positioned to leverage the MANF opportunity for Amarantus shareholders and Parkinson's patients because of the expansive intellectual property (IP) portfolio the Company owns, including composition of matter patents in the US and Europe, use patents worldwide and provisional delivery dosing patents that have been filed based on today's data, extending marketing exclusivity for MANF through 2031. This IP position may make MANF more attractive to a potential partner than other neurotrophic factors in development that do not have the same patent runway."

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual pro
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
(Date:1/23/2015)... BIRMINGHAM, Ala. , Jan. 23, 2015 Gem ... (STS) patients have been enrolled into the Company,s Phase ... efficacy and safety of Gem,s lead compound, GPX-150 (an ... for advanced or metastatic disease. Logo - ...
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE ... specializes in the development and sale of patented biopharmaceutical ... active pharmaceutical ingredients (API) today announced the business and ... operation. 1. Following the September 2014 JCM ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... , RALEIGH, N.C., Nov. 24 Pharmaceutical ... pharmaceutical and biotech industry, today announced the launch of a ... Hospital Marketplace e-course is the newest addition to ... series of e-courses designed to fill the critical need for ...
... , SALT ... City based software company, announces the launch of a new online vision ... with existing in-office therapy methods. , eyeQ was introduced at ... Brad Habermehl believes the eyeQ program adds significant value to ...
Cached Medicine Technology:Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 3Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... , ... the first annual awards program saluting individual health care professionals who inspire, motivate and empower ... sector of the healthcare industry. The Dorland Health People Awards is calling for entries now, ... ...
... study appearing in the journal PLoS ONE, ... mathematical patterns underlying the way individuals unconsciously distribute ... their environment. These patterns appear to meet ... is a scientific law and, if confirmed in ...
... research illustrates that some patients with transformed lymphoma showed ... side effects. The international study, involving 24 medical ... presented at the American Society of Clinical Oncology ( ... Forty-five percent of patients with transformed lymphoma ...
... that triggers the need for a night,s rest may be ... -- Brain injuries can disrupt the body,s production of the ... suggests. , "We,ve known that people often have problems with ... about the exact causes of these problems," study author Shantha ...
... ... specializes in aging across the lifespan and brain health, recently identified OASIS a “health-promoting ... (Vocus) ... health, connect with others, build skills and serve the community. For over 25 ...
... VIEW, Calif. May 26, 2010 Complete Genomics ... that Genentech Inc., a wholly owned member of the ... company,s sequencing, bioinformatics and analytics services to sequence and ... tissue. Tumor-normal pairs like this allow researchers to compare ...
Cached Medicine News:Health News:Dorland Health Announces People Awards Honoring Excellence & Dedication Among Healthcare Professionals - Call For Entries 2Health News:Study finds 'law-like' patterns in human preference behavior 2Health News:Study finds 'law-like' patterns in human preference behavior 3Health News:Study identifies promising treatment for aggressive lymphoma 2Health News:Brain Injuries May Lead to Sleep Woes 2Health News:Brain Health Expert Says OASIS Promotes Brain Fitness 2Health News:Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature 2
... Intended for the quantitative ... in serum or plasma. Two ... Phosphate tablets must be purchased ... method. Kinetic reaction. Wavelength: 340 ...
For the quantitative determination of total protein concentration in human serum....
For the determination of urea nitrogen in human serum....
Intended for the quantitative determination of urea nitrogen in serum. Reaction: kinetic. Wavelength: 340 nm. Linearity: 150 mg/dL (53.4 mmol/L urea) at 37C....
Medicine Products: